Technical Analysis for IDRA - Idera Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade D 7.48 0.13% 0.01
IDRA closed up 0.13 percent on Friday, November 16, 2018, on 46 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical IDRA trend table...

Date Alert Name Type % Chg
Nov 16 20 DMA Support Bullish 0.00%
Nov 16 Wide Bands Range Expansion 0.00%
Nov 15 Crossed Above 20 DMA Bullish 0.13%
Nov 15 Calm After Storm Range Contraction 0.13%
Nov 15 NR7 Range Contraction 0.13%
Nov 15 Inside Day Range Contraction 0.13%
Nov 15 Wide Bands Range Expansion 0.13%
Nov 14 Fell Below 20 DMA Bearish 4.32%
Nov 14 Wide Bands Range Expansion 4.32%
Nov 14 Down 3 Days in a Row Weakness 4.32%

Older signals for IDRA ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Idera Pharmaceuticals, Inc., a clinical stage biotechnology company, engages in the discovery and development of novel synthetic DNA- and RNA- based drug candidates. It is developing drug candidates designed to modulate immune responses mediated through Toll-like Receptors (TLRs); and evaluating gene silencing oligonucleotides (GSOs), which inhibit the production of disease-associated proteins by targeting RNA. The company focuses on developing products for the treatment of autoimmune and inflammatory diseases. Its autoimmune and inflammatory disease programs include IMO-3100, an antagonist of TLR7 and TLR9, which has completed Phase II clinical trials for the treatment of psoriasis; and IMO-8400, an antagonist of TLR7, TLR8, and TLR9 that is in Phase I clinical trials for the treatment of psoriasis/lupus. The company's cancer program comprises IMO-2055, which has completed Phase Ib clinical trials for treatment of non-small cell lung cancer; and has completed Phase II clinical trials for the treatment of squamous cell, head and neck, and colorectal cancer. It is also developing IMO-2134 that has completed Phase I clinical trials to treat asthma and allergy. In addition, the company's research candidates include IMO-4200 for hematologic malignancies; and TLR3 Agonists for infectious diseases and other applications, as well as gene silencing oligonucleotides for inhibition of gene expression by targeting RNA. The company has license agreement with Merck KGaA to research, develop, and commercialize products containing its TLR9 agonists for the treatment of cancer; and license and research collaboration agreement with Merck Sharp & Dohme Corp. to research, develop, and commercialize vaccine products containing its TLR7, 8, and 9 agonists in the fields of cancer, infectious diseases, and Alzheimer's disease. Idera Pharmaceuticals, Inc. was founded in 1989 and is based in Cambridge, Massachusetts.
Is IDRA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 20.4
52 Week Low 5.2
Average Volume 282,414
200-Day Moving Average 11.363
50-Day Moving Average 8.1168
20-Day Moving Average 7.427
10-Day Moving Average 7.838
Average True Range 0.7567
ADX 20.51
+DI 19.0493
-DI 21.7365
Chandelier Exit (Long, 3 ATRs ) 7.2799
Chandelier Exit (Short, 3 ATRs ) 8.6801
Upper Bollinger Band 8.8019
Lower Bollinger Band 6.0521
Percent B (%b) 0.52
BandWidth 37.024371
MACD Line -0.1064
MACD Signal Line -0.1362
MACD Histogram 0.0298
Fundamentals Value
Market Cap 1.12 Billion
Num Shares 150 Million
EPS -0.34
Price-to-Earnings (P/E) Ratio -22.00
Price-to-Sales 13.60
Price-to-Book 2.94
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 8.28
Resistance 3 (R3) 8.22 7.89 8.15
Resistance 2 (R2) 7.89 7.69 7.92 8.10
Resistance 1 (R1) 7.69 7.56 7.79 7.75 8.06
Pivot Point 7.36 7.36 7.41 7.39 7.36
Support 1 (S1) 7.15 7.15 7.26 7.21 6.90
Support 2 (S2) 6.82 7.03 6.85 6.86
Support 3 (S3) 6.62 6.82 6.81
Support 4 (S4) 6.68